ReviewCancer science2026
MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy.
Review in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The homozygous deletion of the chromosome 9p21.3 locus, which includes cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) and methylthioadenosine phosphorylase (MTAP) genes, is one of the most common genomic alterations in cancer. MTAP encodes an essential enzyme in the methionine salvage pathway. Historically, deletions at this locus have been characterized primarily by cell cycle dysregulation driven by CDKN2A/B loss. However, recent studies have revealed that the co-deletion of MTAP exposes profound metabolic vulnerabilities. Loss of the MTAP function increases cellular dependency on protein arginine methyltransferase 5 (PRMT5). Consequently, targeted PRMT5 inhibition effectively induces synthetic lethality specifically in MTAP-deleted tumors. Based on this unique mechanism, the development of novel therapeutic agents exploiting this synthetic lethality is actively underway. In this review, we provide a comprehensive overview of the physiological roles of the MTAP-PRMT5 axis and the mechanistic principles underlying this synthetic lethality in MTAP-deficient cells. Furthermore, drawing upon insights from the analysis of real-world patient data, we discuss the clinical and molecular characteristics of MTAP-deleted tumors, review the landscape of ongoing clinical trials, and explore novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.